Shukla Sath's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Aug 6, 2024
- Accession no.
- 0000950170-24-092170
- Filed
- Aug 6, 2024
- Trade date
- Aug 2-5, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $42.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SathCIK 0001782817 | Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 2, 2024 | Common Stock | SSaleDisposed | −14,800 | $1.32 | −$19,536 | 1,161,207 | Direct | |
| Aug 5, 2024 | Common Stock | SSaleDisposed | −17,641 | $1.31 | −$23,109.71 | 1,143,566 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.